Ota et al. also reported that expression of PD-L1 was suppressed by inhibitors of the MEK–ERK and PI3K–AKT signaling pathways in NSCLC cells positive for either EML4–ALK or activating mutations of the EGFR [15]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.